CD19 and autoimmune disease: Numerous preclinical and clinical studies have shown the efficacy of anti-CD19 and anti-BCMA CAR-T cells in treating a range of autoimmune diseases, including SLE, by targeting CD19+ B cells or BCMA+ plasma cells or double-positive plasmablasts (32, 33).